[](http://www.cell.com/content/curren)

10/01/2019

**Prematurely ended - statement**

**EudraCT number:** 2006-006212-30

**Full title of the study:** A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy (HAART).

**Study Contact:** Nesrina Imami

**Sponsor:** Imperial College London

**Contact email address:** n.imami@imperial.ac.uk

**Date of the early termination of the trial:** 01.10.2011

**Statement on discontinuation of the study:** Study prematurely ended due to 12 patients recruited



Elizabeth Magnusson

Research Integrity Officer

Research Office

Room 221, Medical School Building

St Mary’s Campus

Norfolk Place

London W2 1PG

e.magnusson@imperial.ac.uk